Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)

Manuel Santamaria; Olaf Neth; Jo A. Douglass; Gergely Krivan; Robin Kobbe; Ewa Bernatowska; Sofia Grigoriadou; Claire Bethune; Anita Chandra; Gerd Horneff; Michael Borte; Anja Sonnenschein; Pavlina Kralickova; Silvia Sánchez Ramón; Daman D. Langguth; Luis Ignacio Gonzalez‑Granado; Laia Alsina; Montse Querolt; Rhonda Griffin; Carrie Hames; Elsa Mondou; Jeffrey Price; Ana Sanz; Jiang Lin

doi:10.1007/s10875-022-01219-3

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)

Manuel Santamaria
, Olaf Neth
, Jo A. Douglass
, Gergely Krivan
, Robin Kobbe
, Ewa Bernatowska
, Sofia Grigoriadou
, Claire Bethune
, Anita Chandra
, Gerd Horneff
, Michael Borte
, Anja Sonnenschein
, Pavlina Kralickova
, Silvia Sánchez Ramón
, Daman D. Langguth
, Luis Ignacio Gonzalez‑Granado
, Laia Alsina^*
, Montse Querolt
, Rhonda Griffin
, Carrie Hames

Elsa Mondou, Jeffrey Price, Ana Sanz, Jiang Lin

^*Corresponding author for this work

Hospital Universitario Reina Sofía
Hospital Universitario Virgen del Rocio
Royal Melbourne Hospital
University of Melbourne
Szent Laszlo Hospital
University of Hamburg
Children's Memorial Health Institute
Royal London Hospital
University Hospitals Plymouth NHS Trust
University of Cambridge
Asklepios Kinderklinik Sankt Augustin
University of Cologne
Klinikum St. Georg Leipzig
Johannes Gutenberg University Mainz
Charles University
Hospital Clínico San Carlos de Madrid
Sullivan Nicolaides Pathology
Hospital Universitario 12 de Octubre
SJD Barcelona Children's Hospital
Institut de Recerca Sant Joan de Déu
University of Barcelona
Grifols Bioscience Industrial Research Group
Grifols Bioscience R&D Research Group

Research output: Contribution to journal › Comment/debate

Abstract

Due to typesetting mistake, the author’s corrections were missed. The original version has been corrected.

Original language	English
Pages (from-to)	512-513
Number of pages	2
Journal	Journal of Clinical Immunology
Volume	42
Issue number	3
DOIs	https://doi.org/10.1007/s10875-022-01219-3
Publication status	Published - Apr 2022
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1007/s10875-022-01219-3

Fingerprint

Dive into the research topics of 'Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)'. Together they form a unique fingerprint.

Cite this

Santamaria, M., Neth, O., Douglass, J. A., Krivan, G., Kobbe, R., Bernatowska, E., Grigoriadou, S., Bethune, C., Chandra, A., Horneff, G., Borte, M., Sonnenschein, A., Kralickova, P., Ramón, S. S., Langguth, D. D., Gonzalez‑Granado, L. I., Alsina, L., Querolt, M., Griffin, R., ... Lin, J. (2022). Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6). Journal of Clinical Immunology, 42(3), 512-513. https://doi.org/10.1007/s10875-022-01219-3

Santamaria, Manuel ; Neth, Olaf ; Douglass, Jo A. et al. / Correction to : A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6). In: Journal of Clinical Immunology. 2022 ; Vol. 42, No. 3. pp. 512-513.

@article{cccc30a7f0de49c785b0dff61ebf97b8,

title = "Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20\% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)",

abstract = "Due to typesetting mistake, the author{\textquoteright}s corrections were missed. The original version has been corrected.",

author = "Manuel Santamaria and Olaf Neth and Douglass, \{Jo A.\} and Gergely Krivan and Robin Kobbe and Ewa Bernatowska and Sofia Grigoriadou and Claire Bethune and Anita Chandra and Gerd Horneff and Michael Borte and Anja Sonnenschein and Pavlina Kralickova and Ram{\'o}n, \{Silvia S{\'a}nchez\} and Langguth, \{Daman D.\} and Gonzalez‑Granado, \{Luis Ignacio\} and Laia Alsina and Montse Querolt and Rhonda Griffin and Carrie Hames and Elsa Mondou and Jeffrey Price and Ana Sanz and Jiang Lin",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = apr,

doi = "10.1007/s10875-022-01219-3",

language = "English",

volume = "42",

pages = "512--513",

journal = "Journal of Clinical Immunology",

issn = "0271-9142",

publisher = "Springer",

number = "3",

}

Santamaria, M, Neth, O, Douglass, JA, Krivan, G, Kobbe, R, Bernatowska, E, Grigoriadou, S, Bethune, C, Chandra, A, Horneff, G, Borte, M, Sonnenschein, A, Kralickova, P, Ramón, SS, Langguth, DD, Gonzalez‑Granado, LI, Alsina, L, Querolt, M, Griffin, R, Hames, C, Mondou, E, Price, J, Sanz, A & Lin, J 2022, 'Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)', Journal of Clinical Immunology, vol. 42, no. 3, pp. 512-513. https://doi.org/10.1007/s10875-022-01219-3

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6). / Santamaria, Manuel; Neth, Olaf; Douglass, Jo A. et al.
In: Journal of Clinical Immunology, Vol. 42, No. 3, 04.2022, p. 512-513.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)

AU - Santamaria, Manuel

AU - Neth, Olaf

AU - Douglass, Jo A.

AU - Krivan, Gergely

AU - Kobbe, Robin

AU - Bernatowska, Ewa

AU - Grigoriadou, Sofia

AU - Bethune, Claire

AU - Chandra, Anita

AU - Horneff, Gerd

AU - Borte, Michael

AU - Sonnenschein, Anja

AU - Kralickova, Pavlina

AU - Ramón, Silvia Sánchez

AU - Langguth, Daman D.

AU - Gonzalez‑Granado, Luis Ignacio

AU - Alsina, Laia

AU - Querolt, Montse

AU - Griffin, Rhonda

AU - Hames, Carrie

AU - Mondou, Elsa

AU - Price, Jeffrey

AU - Sanz, Ana

AU - Lin, Jiang

PY - 2022/4

Y1 - 2022/4

N2 - Due to typesetting mistake, the author’s corrections were missed. The original version has been corrected.

AB - Due to typesetting mistake, the author’s corrections were missed. The original version has been corrected.

UR - https://www.scopus.com/pages/publications/85124815559

U2 - 10.1007/s10875-022-01219-3

DO - 10.1007/s10875-022-01219-3

M3 - Comment/debate

C2 - 35174440

AN - SCOPUS:85124815559

SN - 0271-9142

VL - 42

SP - 512

EP - 513

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

IS - 3

ER -

Santamaria M, Neth O, Douglass JA, Krivan G, Kobbe R, Bernatowska E et al. Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6). Journal of Clinical Immunology. 2022 Apr;42(3):512-513. doi: 10.1007/s10875-022-01219-3

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this